Blogs

Lyrebird Health, the AI clinical documentation platform, today announced the appointment of Dr. Ray Boyapati as Chief Clinical Officer. The appointment signals a defining moment for Lyrebird: a deliberate, company-wide commitment to building AI that clinicians, health systems, and patients can trust completely.

Good technology is not enough. What healthcare needs is AI that works at the point where it matters most: the interaction between clinician and patient. That requires clinical leadership that understands what practice actually looks like from the inside, and the organisational commitment to build around that reality. Dr. Ray Boyapati is a consultant gastroenterologist at Monash Health specialising in inflammatory bowel disease, Adjunct Senior Lecturer at Monash University, and holds a doctorate from the University of Edinburgh. His peer-reviewed research has been cited over 1,900 times, a body of work that reflects both the rigour and the clinical stakes he brings to every problem he works on. Ray is passionate about advocating for clinicians, and quality and equitable care for patients. He is a nationally recognised medical leader, and current chair of the IBD faculty of the Gastroenterology Society of Australia (GESA) where has led projects to improve access to high-quality gastroenterology care. He joins Lyrebird with a mandate to embed clinical rigour into the DNA of the product, not as a feature, but as a foundation.

The NHS across South West London is deploying Lyrebird Health's ambient AI platform to support up to 20,000 clinicians over the next four years, representing the largest deployment of ambient voice technology in the UK to date.

Lyrebird Health and Ochre Health have partnered to deliver and support high-quality primary care across their network of medical centres

AI tools are increasingly part of routine clinical workflows in general practice, requiring clinicians to examine and apply existing standards for privacy, consent, and clinical safety to these new technologies.

AI tools are increasingly part of routine clinical workflows in general practice, requiring clinicians to examine and apply existing standards for privacy, consent, and clinical safety to these new technologies.

AI tools are increasingly part of routine clinical workflows in general practice, requiring clinicians to examine and apply existing standards for privacy, consent, and clinical safety to these new technologies.

The Therapeutic Goods Administration published guidance on digital scribes in August 2025, consolidating a regulatory position that had been developing across 2024 and 2025. The TGA's digital scribes guidance page addresses when a digital scribe is regulated as a medical device under the Therapeutic Goods Act 1989, what responsibilities apply when it is, and what practices and clinicians should understand about the products they are using.

Patients have the ethical and legal right to make informed decisions about their health. Informed consent is the basis for many Privacy Act exceptions, permitting collection, use and disclosure.